Article

‘Mylan Pharmaceuticals giving tough fight to bend the curve of COVID-19’

naresh

Working alongside the central government and state governments Mylan Pharmaceutical Pvt Ltd is relentlessly working towards ensuring that quality medicines reach people across the country, to fight against COVID-19 and other diseases.

Speaking at different occasion of the first edition of Healthcare Transformation Summit, Naresh Hasija, Associate Vice President , Mylan Pharmaceutical Pvt Ltd said, “We supply our medicines to 165 countries. During COVID-19 pandemic our foremost importance was to protect our staff, particularly in the factories and manufacturing facilities. Myan supplies remdesivir medicine directly to 15 state governments and our huge manufacturing facilities can produce half a billion vile and we can scale it up at any moment. We make sure that essential drugs will not be of short supply.”

Receiving the Healthcare Excellence Award for best project – supporting the government mission to end TB in the presence of Ashwini Kumar Choubey, Minister of State, Ministry of Health and Family Welfare (MoHFW) Hasija informed that with the guidance of the central government they have surveyed 10 lakh people for MDR and XDR tuberculosis.

Also read: Role of IT in Healthcare Transformation

“We as a pharmaceutical company have come forward to serve the nation with our medicines which can treat moderate to severe cases of COVID-19. Remdesivir is used for hospitalised patients whose oxygen levels are low. Apart from COVID-19, we are also present in the space of viral Hepatitis, MDR and XDR tuberculosis and HIV,” he added.

Talking about the role of IT in healthcare transformation, he said, “We are a research-based organization. For us, integrating IT from research to manufacturing is an important aspect. During COVID times, Mylan pharmaceuticals has created a digital supply chain and started to distribute remdesivir across India. We have anti diversion laws and also have a mandate from DCGI to collect patient consent forms for every patient and medicine should be made available in COVID-19 hospitals. We have a robust surveillance system on our distribution network. It is a huge enabler. It has many applications including knowledge dissemination.”

Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on


Most Popular

SUBSCRIBE OUR NEWSLETTER
200000+ Subscribers read it every day.
Subscribe Newsletter
To Top